Mostrando 10 resultados de: 36
Publisher
Journal of Nanobiotechnology(3)
Molecular Neurobiology(3)
Nanomaterials(3)
Frontiers in Aging Neuroscience(2)
Nanomedicine(2)
Área temáticas
Farmacología y terapéutica(26)
Enfermedades(25)
Medicina y salud(13)
Fisiología humana(7)
Ginecología, obstetricia, pediatría, geriatría(4)
Área de conocimiento
Farmacología(12)
Neurología(10)
Nanopartícula(8)
Biotecnología(7)
Ciencia de materiales(4)
Origen
scopus(36)
Comparative study of Ex Vivo transmucosal permeation of pioglitazone nanoparticles for the treatment of Alzheimer's disease
ArticleAbstract: Pioglitazone has been reported in the literature to have a substantial role in the improvement of ovPalabras claves:Alzheimer's disease, Nanoparticles, Pioglitazone, PLGA-PEG, Transmucosal permeationsAutores:Calpena A.C., Espina M., García M.L., Halbaut L., Lupe Carolina Espinoza, Silva-Abreu M.Fuentes:scopusBenzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia
ArticleAbstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to theirPalabras claves:Alzheimer's disease, benzodiazepines, COGNITION, dementia, RISK FACTORSAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusBiodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges
ReviewAbstract: Epilepsy is the second most prevalent neurological disease worldwide. It is mainly characterized byPalabras claves:Epilepsy, lipid nanoparticles, Nanomedicine, nanotechnology, neurodegenerative diseases, Polymeric nanoparticlesAutores:Antoni Camins, Bonilla L., Cano A., Espina M., Esteruelas G., Ettcheto M., García M.L., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusA metabolic perspective of late onset Alzheimer's disease
ReviewAbstract: After decades of research, the molecular neuropathology of Alzheimer's disease (AD)is still one of tPalabras claves:Alzheimer's disease, c-Jun N-terminal kinase inhibitors, Insulin, Licochalcone A, neuroinflammation, Reticulum stress, Type 2 Diabetes mellitusAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E., Zárate C.B.Fuentes:scopusDevelopment of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
ArticleAbstract: Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low waPalabras claves:cell-penetrating peptides, Licochalcone-A, Nanoparticles, Ocular inflammation, PLGAAutores:Antoni Camins, Cano A., Espina M., Ettcheto M., Galindo R., García M.L., Gómara M.J., Haro I., Sanchez-Lopez E.Fuentes:scopusDevelopment of a nasal donepezil-loaded microemulsion for the treatment of Alzheimer’s disease: In vitro and Ex vivo characterization
ArticleAbstract: Background: Donepezil (DPZ) is widely prescribed as a specific and reversible acetylcholinesterase iPalabras claves:Alzheimer’s disease, Delivery systems, Donepezil, Intranasal route, Microemulsion, permeationAutores:Calpena A.C., Clares-Naveros B., Fábrega M.J., García M.L., Lupe Carolina Espinoza, Vacacela M.Fuentes:scopusDexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways
ArticleAbstract: The aim of the present study is to elucidate the neuronal pathways associated to NSAIDs causing a rePalabras claves:Alzheimer's disease, APPswe/PS1dE9, Dexibuprofen, hippocampus, insulin receptor, Memory impairment, Mitochondria, TauAutores:Antoni Camins, Auladell C., Busquets O., Ettcheto M., Folch J., García M.L., Olloquequi J., Pallás M., Pons L., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusCorrection to: Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer’s Disease (Molecular Neurobiology, (2018), 55, 9, (7327-7339), 10.1007/s12035-018-0868-4)
OtherAbstract: The original version of this article unfortunately contained mistake. The authors found that Fig. 4.Palabras claves:Autores:Antoni Camins, Auladell C., Busquets O., Cabrera H., Carrera M.V., Carro E., Casadesús G., Ettcheto M., Folch J., García M.L., Gómez-Mínguez Y., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusCurrent Research Therapeutic Strategies for Alzheimer's Disease Treatment
ReviewAbstract: Alzheimer's disease (AD) currently presents one of the biggest healthcare issues in the developed coPalabras claves:Autores:Abad S., Antoni Camins, Auladell C., Ettcheto M., Folch J., García M.L., Olloquequi J., Petrov D., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusCurrent advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases
ReviewAbstract: Effective intervention is essential to combat the coming epidemic of neurodegenerative (ND) diseasesPalabras claves:brain disorders, Brain targeting, CNS nanomedicine, neurodegenerative diseases, neurological diseases, Polymeric nanoparticlesAutores:Antoni Camins, Cano A., Espina M., Ettcheto M., Galindo R., García M.L., Lopez-Machado A.L., Sanchez-Lopez E., Souto E.M.B., Turowski P.Fuentes:scopus